Treatment of Kynurenin-producing Tumors with AhR Antagonists
Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxins has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation. The TDO-AHR pathway is active in human brain tumors and associated with malignant progression and poor survival. As Kyn is produced during cancer progression and inflammation in the local microenvironment in amounts sufficient for activating the human AHR, these results can be used to develop a specific chemotherapy to manipulate AhR activated signal pathways in susceptible cancer cells. Using this mechanism more treatment opportunities can be used and different tumor types can be treated by AhR related drugs.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…
